| DB ID | MyCo_2547 |
| Title | Galactomannan antigenemia for the diagnosis of invasive aspergillosis in neutropenic patients with hematological disorders |
| Year | 2006 |
| PMID | 17205865 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Neutropenic Patients with Hematological Disorders |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The present study was approved by the institutional review board of King Chulalongkorn Memorial Hospital (KCMH), Bangkok, Thailand. Informed consent was obtained from patients or their legal guardians. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomann |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Thailand |
| Cohort | The authors prospectively performed the study from June 2002 to January 2004 in a consecutive series of adult patients with hematological disorders who were at risk for developing IA at KCMH, Bangkok, Thailand. Eligible patients were 1) receiving chemotherapy with an expected duration of neutropenia of less than 500 cells/µL of at least 7 days or 2) undergoing allogeneic bone marrow or peripheral blood stem cell transplantation. Those patients, who were under- going autologous bone marrow transplantation or less than 16 years old, were excluded from the present study. All patients were hospitalized, and antifungal prophylaxis with itraconazole oral solution (200-400 mg/day) was given twice a day throughout the period of neutropenia. Broad-spectrum antibiotics were empirically initiated at the first febrile episode of neutropenic patient according to the guidelines of Infectious Diseases Society of America. Patients, who had persistent fever after 5-7 days of appropriate antibiotic treatment, received amphotericin B (amphotericin B deoxy-cholate: 0.8-1.2 mg/kg/day or liposomal amphotericin B: 3-5 mg/kg/day) until the resolution of fever and neutropenia. During hospitalization, blood samples were obtained once or twice weekly until death or discharge from the hospital. |
| Cohort No. | 44 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.941 |
| Specificity | 0.788 |
| Positive Predictive Value | 0.696 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal infections (IFIs) particularly invasive aspergillosis (IA) have been one of the major causes of morbidity and mortality in patients with hematological disorders who receive chemotherapy or undergo hematopoietic stem cell transplantation (HSCT). Early diagnosis of IA may improve the clinical outcome, but it usually requires invasive procedures to obtain specimens for culture and histopathologic examination. Unfortunately, such procedures are often precluded by thrombocytopenia or by the critical condition of the patients. |
| Technique | Immunological assay |
| Analysis Method | ELISA Based |
| ELISA kits | Platellia Aspergillus EIA test kit (Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
